偏头痛是一种长期常见的、周期性反复发作的神经血管性疾病,发作时伴有中重度搏动样头痛,单侧常见,或双侧交替发作或累及双侧,伴随某些自主神经症状,如惧声、恶心、呕吐、畏光等,具有发病时间长、病情迁延、难于治愈等特点。可发生于任何年龄,首次发病多见于青春期。女性患病率高于男性。偏头痛对生活质量的影响很大,世界...
英文同义词: 2,4,6-trifluoro-N-{6-[(1-methylpiperidine-4-yl)carbonyl]pyridin-2-yl}benzamide hemisuccinate;LASMIDITAN SUCCINATE;Lasmiditan hemisuccinate;Lasmiditan succinate (USAN);2,4,6-Trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]benzamide,butanedioic acid(1:2);Lasmidi...
半琥珀酸拉米地坦中间体 lasmiditan hemisuccinate Intermediate 首页ꄲ医药中间体ꄲ半琥珀酸拉米地坦中间体 lasmiditan hemisuccinate Intermediate 半琥珀酸拉米地坦中间体 lasmiditan hemisuccinate Intermediate ꄴ上一个:鲁马卡托中间体 Lumacaftor Intermediate ꄲ下一个:非戈替尼中间体 Filgotinib Intermediate...
Active ingredient:lasmiditan hemisuccinate Inactive ingredients:croscarmellose sodium, magnesium stearate, microcrystalline cellulose, pregelatinized starch, sodium lauryl sulfate. Color mixture ingredients: black ferric oxide, polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide. 100 mg tablets also co...
戊戌数据合成工艺数据库提供CAS:439239-92-6的合成工艺信息查询,包括Lasmiditan hemisuccinate的基本信息,合成工艺流程图,拉米地坦合成工艺路线图以及原研企业Eli Lilly And Company的信息查询检索.
拉米地坦;半琥珀酸;Lasmiditan hemisuccinate;偏头痛;急性;5-HT1F受体抑制药; 入库时间2024-04-22 18:50:12 引文网络 参考文献 引证文献 共引文献 同被引文献 二级参考文献 二级引证文献 1.Lasmiditan for the treatment of migraine[J].Matilde Capi;Fernando de Andrés;Luana Lionetto;Giovanna Gentile;Fabiol...
中文名称:Lasmiditan succinate (USAN) 英文别名:butanedioic acid,2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)pyridin-2-yl]benzamide;LASMIDITAN SUCCINATE;Lasmiditan hemisuccinate;W64YBJ346B;LY683974;2,4,6-Trifluoro-N-(6-((1-methylpiperidine-4-yl)carbonyl)pyridin-2-yl)benzamide succ...
拉米地坦 / 半琥珀酸 / Lasmiditan hemisuccinate / 偏头痛 / 急性 / 5-HT1F受体抑制药 引用本文 导出引用 陈本川. 治疗急性偏头痛新药——半琥珀酸拉米地坦(lasmiditan hemisuccinate)[J]. 医药导报, 2020, 39(6): 887-895 https://doi.org/10.3870/j.issn.1004-0781.2020.06.034 参考文献 原文顺序...
治疗急性偏头痛新药--半琥珀酸拉米地坦(lasmiditan hemisuccinate)
and/or prevention of migraine, and in particular for the prevention of therapy resistant migraines, comprising administration of a total nightly dose of 25-200 mg lasmiditan, or a pharmaceutically acceptable salt thereof, such as the hemisuccinate salt, and a pharmaceutically acceptable diluent or ...